Articles Related to clinical trials

Dentin hypersensitivity (DH) is generally described as “a brief, sharp, and acute pain emanating from exposed dentin in response to thermal, tactile, osmotic, or chemical stimuli, as well as exposure to air that cannot be attributed to any dental anomaly or pathology”.

View complete article: PDF  |  Full-text

Seventeen alpha hydroxyprogesterone caproate (17-OHPC) is the only FDA-approved drug labeled for prevention of preterm delivery. This drug is also available as a compounded product from licensed compounding pharmacies. This article reviews the FDA approval history and pharmacy compounding quality control data of 17-OHPC, as well as briefly discusses possible future pharmaceutical development strategies for 17-OHPC.

View complete article: PDF  |  Full-text

In this study, we focused on the effect of β-glucan supplementation of children with chronic respiratory problems. We measured the levels of cortisol, salivary IgE and cotinine in 56 children and evaluated the effect of 30 day supplementation with 100 mg/day oral dose of yeast-derived β-glucan. Our results showed strong decrease of cotinine and cortisol levels in saliva of β-glucan-supplemented children.

View complete article: PDF  |  Full-text

Capsaicin, an active ingredient of Capsicum fruit, is currently undergoing “revival” in the clinical management of pain. However, the choice of its formulation is rather limited to the use of “old-fashioned” tinctures and recently the patches. In an attempt to improve the therapeutic outcome and develop its skin-friendly formulation, we prepared the vesicle-based drug delivery system with capsaicin.

View complete article: PDF  |  Full-text  | Digital